Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (NCT06449209)

🧪 Interventions in This Study

• BNT327 Dose Level 1 (DL1) (DRUG)
• BNT327 Dose Level 2 (DL2) (DRUG)
• Etoposide (DRUG)
• Carboplatin (DRUG)
• Paclitaxel (DRUG)
• Topotecan (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (64 Sites)

Showing the first 25 of 64 sites.

• Alaska Oncology and Hematology, LLC — Anchorage, Alaska
• Valkyrie Clinical Trials — Los Angeles, California
• Clermont Oncology Center — Clermont, Florida
• Hematology Oncology Associates of Treasure Coast — Port Saint Lucie, Florida
• Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists — Tallahassee, Florida
• Carle Foundation Hospital d/b/a Carle Cancer Center — Urbana, Illinois
• Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
• University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center) — Lexington, Kentucky
• Allina Health — Minneapolis, Minnesota
• SSM Health Cancer Care - St. Clare — Fenton, Missouri
• Nebraska Hematology-Oncology (NHO) - Lincoln — Lincoln, Nebraska
• Clinical Research Alliance Inc — Westbury, New York
• Haywood Infusion Center — Clyde, North Carolina
• FirstHealth Outpatient Cancer Center — Pinehurst, North Carolina
• The Christ Hospital Cancer Center — Cincinnati, Ohio
• University of Tennessee Medical Center — Knoxville, Tennessee
• Millenium Research & Clinical Development — Houston, Texas
• SSM Health Cancer Care — Madison, Wisconsin
• Lyell McEwin Hospital — Adelaide,
• St. Vincent's Hospital — Fitzroy,
• Peninsula Oncology Centre — Frankston,
• Royal North Shore Hospital — St Leonards,
• Westmead Hospital — Westmead,
• Chungbuk National University Hospital — Cheongju-si,
• Yeungnam University Medical Center — Daegu,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive-stage Small-cell Lung Cancer

• Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Springdale, Arkansas
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Mobile, Alabama
• MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer — Washington D.C., District of Columbia
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC — Los Angeles, California
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Tucson, Arizona

Explore by condition: All Extensive-stage Small-cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.